Open-label, Dose-escalation, Multiple Dosing Study to Evaluate the Safety, Tolerability, Immune Response and Pre Efficacy of BVAC-C in Patients With Multiple Metastatic Progressive or Recurrent HPV Type 16 or 18 Positive Cervical Cancer After Failure to Standard Care
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2018
At a glance
- Drugs BVAC C (Primary)
- Indications Cervical cancer
- Focus Adverse reactions
- Sponsors Cellid Company
- 29 Jan 2018 Planned End Date changed from 1 Aug 2017 to 1 Aug 2020.
- 29 Jan 2018 Planned primary completion date changed from 1 Aug 2017 to 1 Apr 2018.
- 10 Jun 2017 Biomarkers information updated